Therapy-Related Acute Myelogenous Leukemia

  • Gabriela Bernadeta Iwanski
  • Nils Heinrich Thoennissen
  • Dorothy J. Park
  • H. Phillip Koeffler


Therapy-related acute myelogenous leukemia (t-AML) is a recognizable subclass of acute myelogenous leukemia (AML). Features of the syndrome include a preleukemic phase several years after chemotherapy and/or radiation therapy for a primary disease, distinct chromosomal abnormalities in the preleukemic and leukemic cells, and a short survival after the development of leukemia. Therapy-related leukemia has become increasingly common, accounting for 10–20 % of all AMLs. The accelerating incidence can be partly attributed to a variety of factors including longer survival of individuals after successful treatment of their primary malignancy associated with the increasing use of more intensive chemotherapy and/or radiation therapy including hematopoietic stem cell transplantation, frequent use of adjuvant chemotherapy, exposure to various environmental toxins, and greater awareness of this particular diagnosis (Table 24.1). Because of a poor response to therapy, t-AML and therapy-related myelodysplastic syndrome (t-MDS) are among the most feared long-term complications of cancer therapy today.


Myelodysplasia and leukemia Breast cancer and leukemia Testicular cancer and leukemia 



The authors thank the support of the German Cancer Foundation, G.B.I., and the Deutsche Forschungsgemeinschaft (TH 1438/1-1), N.H.T. H.P.K. is the holder of the Mark Goodson endowed Chair in Oncology Research and a member of the Jonsson Cancer and Molecular Biology Institute at UCLA, as well as the Cancer Science Institute of Singapore, and is supported by the National Institutes of Health (NIH; grants 5R01CA026038-31 and U54CA143930-01), as well as the A*STaR award from the National University of Singapore.


  1. 1.
    Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937.PubMedGoogle Scholar
  2. 2.
    Anderson RL, Bagby GC, Richert-Boe K, et al. Therapy-related preleukemic syndrome. Cancer. 1981;47:1867.PubMedGoogle Scholar
  3. 3.
    Dreyfus B. Preleukemic states. I. Definition and classification. II. Refractory anemia with an excess of myeloblasts in the bone marrow (smoldering acute leukemia). Nouv Rev Fr Hematol Blood Cells. 1976;17:33.PubMedGoogle Scholar
  4. 4.
    Koeffler HP, Golde DW. Human myeloid leukemia cell lines: a review. Blood. 1980;56:344.PubMedGoogle Scholar
  5. 5.
    Pedersen-Bjergaard J, Philip P, Mortensen BT, et al. Acute non-lymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. Clinical and cytogenetic characteristics and results of in vitro culture of bone marrow and HLA typing. Blood. 1981;57:712.PubMedGoogle Scholar
  6. 6.
    Kapadia SB, Krause JR, Ellis LD, et al. Induced acute non-lymphocytic leukemia following long-term chemotherapy: a study of 20 cases. Cancer. 1980;45:1315.PubMedGoogle Scholar
  7. 7.
    Papa G, Alimena G, Annino L, et al. Acute non lymphoid leukaemia following Hodgkin’s disease. Clinical, biological and cytogenetic aspects of 3 cases. Scand J Haematol. 1979;23:339.PubMedGoogle Scholar
  8. 8.
    Rowley JD, Alimena G, Garson OM, et al. A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype. Blood. 1982;59:1013.PubMedGoogle Scholar
  9. 9.
    Rowley JD, Golomb HM, Vardiman JW. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood. 1981;58:759.PubMedGoogle Scholar
  10. 10.
    Saarni MI, Linman JW. Preleukemia. The hematologic syndrome preceding acute leukemia. Am J Med. 1973;55:38.PubMedGoogle Scholar
  11. 11.
    Pui CH, Behm FG, Raimondi SC, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989;321:136.PubMedGoogle Scholar
  12. 12.
    Ratain MJ, Kaminer LS, Bitran JD, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987;70:1412.PubMedGoogle Scholar
  13. 13.
    Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am. 1993;7:81.PubMedGoogle Scholar
  14. 14.
    Dohy H, Genot JY, Imbert M, et al. Myelodysplasia and leukaemia related to chemotherapy and/or radiotherapy—a haematological study of 13 cases. Value of macrocytosis as an early sign of bone marrow injury. Clin Lab Haematol. 1980;2:111.PubMedGoogle Scholar
  15. 15.
    Ballen KK, Antin JH. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes. Hematol Oncol Clin North Am. 1993;7:477.PubMedGoogle Scholar
  16. 16.
    Vardiman JW, Golomb HM, Rowley JD, Variakojis D. Acute non-lymphocytic leukemia in malignant lymphoma: a morphologic study. Cancer. 1978;42:229.PubMedGoogle Scholar
  17. 17.
    Khaleeli M, Keane WM, Lee GR. Sideroblastic anemia in multiple myeloma: a preleukemic change. Blood. 1973;41:1.Google Scholar
  18. 18.
    Maldonado JE, Maigne J, Lecoq D. Comparative electron-microscopic study of the erythrocytic line in refractory anemia (preleukemia) and myelomonocytic leukemia. Nouv Rev Fr Hematol Blood Cells. 1976;17:167.PubMedGoogle Scholar
  19. 19.
    Vardiman JW, Coelho A, Golomb HM, Rowley J. Morphologic and cytochemical observations on the overt leukemic phase of therapy-related leukemia. Am J Clin Pathol. 1983;79:525.PubMedGoogle Scholar
  20. 20.
    Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986;4:325.PubMedGoogle Scholar
  21. 21.
    Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood. 1994;83:2780.PubMedGoogle Scholar
  22. 22.
    First International Workshop on Chromosomes in Leukaemia. Chromosomes in acute non-lymphocytic leukaemia. Br J Haematol. 1978;39:311.Google Scholar
  23. 23.
    Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986;4:1748.PubMedGoogle Scholar
  24. 24.
    Pedersen-Bjergaard J, Philip P, Larsen SO, et al. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood. 1990;76:1083.PubMedGoogle Scholar
  25. 25.
    Johansson B, Mertens F, Heim S, et al. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). Eur J Haematol. 1991;47:17.PubMedGoogle Scholar
  26. 26.
    Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43.PubMedGoogle Scholar
  27. 27.
    Le Beau MM, Espinosa R, Neuman WL, et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci USA. 1993;90:5484.PubMedGoogle Scholar
  28. 28.
    Le Beau MM, Epstein ND, O’Brien SJ, et al. The interleukin 3 gene is located on human chromosome 5 and is deleted in myeloid leukemias with a deletion of 5q. Proc Natl Acad Sci USA. 1987;84:5913.PubMedGoogle Scholar
  29. 29.
    Le Beau MM, Lemons RS, Espinosa R, et al. Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemias with a del(5q). Blood. 1989;73:647.PubMedGoogle Scholar
  30. 30.
    Nienhuis AW, Bunn HF, Turner PH, et al. Expression of the human c-fms proto-oncogene in hematopoietic cells and its deletion in the 5q-syndrome. Cell. 1985;42:421.PubMedGoogle Scholar
  31. 31.
    Le Beau MM, Westbrook CA, Diaz MO, et al. Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders. Science. 1986;231:984.PubMedGoogle Scholar
  32. 32.
    Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol. 1992;19:47.PubMedGoogle Scholar
  33. 33.
    List AF, Jacobs A. Biology and pathogenesis of the myelodysplastic syndromes. Semin Oncol. 1992;19:14.PubMedGoogle Scholar
  34. 34.
    Desmond JC, Raynaud S, Tung E, et al. Discovery of epigenetically silenced genes in acute myeloid leukemias. Leukemia. 2007;21:1026.PubMedGoogle Scholar
  35. 35.
    Lehmann S, O’Kelly J, Raynaud S, et al. Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia. 2007;21:1931.PubMedGoogle Scholar
  36. 36.
    Tsui LC, Farrall M, Donis-Keller H. Report of the committee on the genetic constitution of chromosomes 7 and 8. Cytogenet Cell Genet. 1989;51:166.PubMedGoogle Scholar
  37. 37.
    Koike M, Tasaka T, Spira S, et al. Allelotyping of acute myelogenous leukemia: loss of heterozygosity at 7q31.1 (D7S486) and q33-34 (D7S498, D7S505). Leuk Res. 1999;23:307.PubMedGoogle Scholar
  38. 38.
    Kere J, Donis-Keller H, Ruutu T, de la Chapelle A. Chromosome 7 long-arm deletions in myeloid disorders: terminal DNA sequences are commonly conserved and breakpoints vary. Cytogenet Cell Genet. 1989;50:226.PubMedGoogle Scholar
  39. 39.
    Shannon KM, Turhan AG, Chang SS, et al. Familial bone marrow monosomy 7. Evidence that the predisposing locus is not on the long arm of chromosome 7. J Clin Invest. 1989;84:984.PubMedGoogle Scholar
  40. 40.
    Luna-Fineman S, Shannon KM, Lange BJ. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood. 1995;85:1985.PubMedGoogle Scholar
  41. 41.
    Quesnel B, Kantarjian H, Bjergaard JP, et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol. 1993;11:2370.PubMedGoogle Scholar
  42. 42.
    Pedersen-Bjergaard J, Johansson B, Philip P. Translocation (3;21)(q26;q22) in therapy-related myelodysplasia following drugs targeting DNA-topoisomerase II combined with alkylating agents, and in myeloproliferative disorders undergoing spontaneous leukemic transformation. Cancer Genet Cytogenet. 1994;76:50.PubMedGoogle Scholar
  43. 43.
    Cimino G, Moir DT, Canaani O, et al. Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(q21;q23), t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations. Cancer Res. 1991;51:6712.PubMedGoogle Scholar
  44. 44.
    Ziemin-van DP, McCabe NR, Gill HJ, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA. 1991;88:10735.Google Scholar
  45. 45.
    Dimartino JF, Cleary ML. MLL rearrangements in hematological malignancies: Lessons from clinical and biological studies. Br J Haematol. 1999;106:614.PubMedGoogle Scholar
  46. 46.
    Thirman MJ, Gill HJ, Burnett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med. 1993;329:909.PubMedGoogle Scholar
  47. 47.
    Liu H, Cheng EH, Hsieh JJ. MLL fusions: pathways to leukemia. Cancer Biol Ther. 2009;8:1204.PubMedGoogle Scholar
  48. 48.
    Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia. Overview report. Genes Chromosomes Cancer. 2002;33:331.PubMedGoogle Scholar
  49. 49.
    Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer. 2005;5:943.PubMedGoogle Scholar
  50. 50.
    Baccarani M, Bosi A, Papa G. Second malignancy in patients treated by Hodgkin’s disease. Cancer. 1980;46:1735.PubMedGoogle Scholar
  51. 51.
    Bernstein ML, Vekemans MJ. Chromosomal changes in secondary leukemias of childhood and young adulthood. Crit Rev Oncol Hematol. 1986;5:325.PubMedGoogle Scholar
  52. 52.
    Aksoy M, Erdem S. Followup study on the mortality and the development of leukemia in 44 pancytopenic patients with chronic exposure to benzene. Blood. 1978;52:285.PubMedGoogle Scholar
  53. 53.
    The Fourth International Workshop on Chromosomes in Leukemia. A prospective study of acute nonlymphocytic leukemia. Cancer Genet Cytogenet. 1984;11:249.Google Scholar
  54. 54.
    Brandt L, Nilsson PG, Mitelman F. Occupational exposure to petroleum products in men with acute non-lymphocytic leukaemia. BMJ. 1978;1:553.PubMedGoogle Scholar
  55. 55.
    Mitelman F, Brandt L, Nilsson PG. Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphocytic leukemia. Blood. 1978;52:1229.PubMedGoogle Scholar
  56. 56.
    Einhorn N. Acute leukemia after chemotherapy (melphalan). Cancer. 1978;41:44.Google Scholar
  57. 57.
    Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304:441.PubMedGoogle Scholar
  58. 58.
    Greene MH, Boice JD, Greer BE, et al. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med. 1982;307:1416.PubMedGoogle Scholar
  59. 59.
    Coltman CA, Dixon DO. Second malignancies complicating Hodgkin’s disease: a Southwest Oncology Group 10-year followup. Cancer Treat Rep. 1982;66:1023.PubMedGoogle Scholar
  60. 60.
    DeVore R, Whitlock J, Hainsworth JD, Johnson DH. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q. Ann Intern Med. 1989;110:740.PubMedGoogle Scholar
  61. 61.
    Ratain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol. 1992;3:107.PubMedGoogle Scholar
  62. 62.
    Kyle RA. Second malignancies associated with chemotherapeutic agents. Semin Oncol. 1982;9:131.PubMedGoogle Scholar
  63. 63.
    Krikorian JG, Burke JS, Rosenberg SA, Kaplan HS. Occurrence of non-Hodgkin’s lymphoma after therapy for Hodgkin’s disease. N Engl J Med. 1979;300:452.PubMedGoogle Scholar
  64. 64.
    Stegman R, Alexanian R. Solid tumors in multiple myeloma. Ann Intern Med. 1979;90:780.PubMedGoogle Scholar
  65. 65.
    Bizzozero OJ, Johnson KG, Ciocco A. Radiation-related leukemia in Hiroshima and Nagasaki, 1946–1964. I. Distribution, incidence and appearance time. N Engl J Med. 1966;274:1095.PubMedGoogle Scholar
  66. 66.
    Forrest DL, Hogge DE, Nevill TJ, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin’s lymphoma. a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol. 2005;23:7994.PubMedGoogle Scholar
  67. 67.
    Andre M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004;103:1222.PubMedGoogle Scholar
  68. 68.
    Devereux S, Selassie TG, Vaughan HG, et al. Leukaemia complicating treatment for Hodgkin’s disease: the experience of the British National Lymphoma Investigation. BMJ. 1990;301:1077.PubMedGoogle Scholar
  69. 69.
    Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin’s disease. N Engl J Med. 1990;322:7.PubMedGoogle Scholar
  70. 70.
    Cimino G, Papa G, Tura S, et al. Second primary cancer following Hodgkin’s disease: updated results of an Italian multicentric study. J Clin Oncol. 1991;9:432.PubMedGoogle Scholar
  71. 71.
    Abrahamsen JF, Andersen A, Hannisdal E, et al. Second malignancies after treatment of Hodgkin’s disease: the influence of treatment, follow-up time, and age. J Clin Oncol. 1993;11:255.PubMedGoogle Scholar
  72. 72.
    Swerdlow AJ, Douglas AJ, Vaughan HG, et al. Risk of second primary cancer after Hodgkin’s disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin’s disease, and splenectomy. Br J Cancer. 1993;68:1006.PubMedGoogle Scholar
  73. 73.
    Dietrich PY, Henry-Amar M, Cosset JM, et al. Second primary cancers in patients continuously disease-free from Hodgkin’s disease: a protective role for the spleen? Blood. 1994;84:1209.PubMedGoogle Scholar
  74. 74.
    van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol. 1994;12:312.PubMedGoogle Scholar
  75. 75.
    Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med. 1996;334:745.PubMedGoogle Scholar
  76. 76.
    Mauch PM, Kalish LA, Marcus KC, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin’s disease: long-term analysis of risk factors and outcome. Blood. 1996;87:3625.PubMedGoogle Scholar
  77. 77.
    Wolden SL, Lamborn KR, Cleary SF, et al. Second cancers following pediatric Hodgkin’s disease. J Clin Oncol. 1998;16:536.PubMedGoogle Scholar
  78. 78.
    Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484.PubMedGoogle Scholar
  79. 79.
    Howard R, Gilbert E, Lynch CF, et al. Risk of leukemia among survivors of testicular cancer: a population-based study of 42,722 patients. Ann Epidemiol. 2008;18:416.PubMedGoogle Scholar
  80. 80.
    Andrieu JM, Ifrah N, Payen C, et al. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin’s disease. J Clin Oncol. 1990;8:1148.PubMedGoogle Scholar
  81. 81.
    van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al. Leukemia risk following Hodgkin’s disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol. 1994;12:1063.PubMedGoogle Scholar
  82. 82.
    Tarbell NJ, Gelber RD, Weinstein HJ, Mauch P. Sex differences in risk of second malignant tumours after Hodgkin’s disease in childhood. Lancet. 1993;341:1428.PubMedGoogle Scholar
  83. 83.
    Henry-Amar M, Dietrich PY. Acute leukemia after the treatment of Hodgkin’s disease. Hematol Oncol Clin North Am. 1993;7:369.PubMedGoogle Scholar
  84. 84.
    Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin’s disease. N Engl J Med. 1988;318:76.PubMedGoogle Scholar
  85. 85.
    Valagussa P, Santoro A, Fossati BF, et al. Absence of treatment-induced second neoplasms after ABVD in Hodgkin’s disease. Blood. 1982;59:488.PubMedGoogle Scholar
  86. 86.
    Delwail V, Jais JP, Colonna P, et al. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin’s disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol. 2002;118:189.PubMedGoogle Scholar
  87. 87.
    Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 Study. J Clin Oncol. 2009;27:4548.PubMedGoogle Scholar
  88. 88.
    Cadman EC, Capizzi RL, Bertino JR. Acute nonlymphocytic leukemia: a delayed complication of Hodgkin’s disease therapy: analysis of 109 cases. Cancer. 1977;40:1280.PubMedGoogle Scholar
  89. 89.
    Amadori S, Papa G, Anselmo AP, et al. Acute promyelocytic leukemia following ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiotherapy for Hodgkin’s disease. Cancer Treat Rep. 1983;67:603.PubMedGoogle Scholar
  90. 90.
    Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other malignancies following treatment for Hodgkin’s disease. J Clin Oncol. 1986;4:830.PubMedGoogle Scholar
  91. 91.
    Brusamolino E, Baio A, Orlandi E, et al. Long-term events in adult patients with clinical stage IA–IIA nonbulky Hodgkin’s lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res. 2006;12:6487.PubMedGoogle Scholar
  92. 92.
    Pedersen-Bjergaard J, Larsen SO. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin’s disease. N Engl J Med. 1982;307:965.PubMedGoogle Scholar
  93. 93.
    De Gramont A, Louvet C, Krulik M, et al. Preleukemic changes in cases of nonlymphocytic leukemia secondary to cytotoxic therapy. Analysis of 105 cases. Cancer. 1986;58:630.PubMedGoogle Scholar
  94. 94.
    van der Velden JWC, van Putten WL, Guinee VF, et al. Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin’s disease. Int J Cancer. 1988;42:252.PubMedGoogle Scholar
  95. 95.
    Pedersen-Bjergaard J, Ersboll J, Sorensen HM, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin’s lymphomas. Comparison with results obtained in patients treated for Hodgkin’s disease and ovarian carcinoma with other alkylating agents. Ann Intern Med. 1985;103:195.PubMedGoogle Scholar
  96. 96.
    Ingram L, Mott MG, Mann JR, et al. Second malignancies in children treated for non-Hodgkin’s lymphoma and T-cell leukaemia with the UKCCSG regimens. Br J Cancer. 1987;55:463.PubMedGoogle Scholar
  97. 97.
    Travis LB, Curtis RE, Boice JD, et al. Second cancers following non-Hodgkin’s lymphoma. Cancer. 1991;67:2002.PubMedGoogle Scholar
  98. 98.
    Travis LB, Curtis RE, Glimelius B, et al. Second cancers among long-term survivors of non-Hodgkin’s lymphoma. J Natl Cancer Inst. 1993;85:1932.PubMedGoogle Scholar
  99. 99.
    Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin’s lymphoma: a British Cohort Study. J Clin Oncol. 2006;24:1568.PubMedGoogle Scholar
  100. 100.
    Travis LB, Curtis RE, Stovall M, et al. Risk of leukemia following treatment for non-Hodgkin’s lymphoma. J Natl Cancer Inst. 1994;86:1450.PubMedGoogle Scholar
  101. 101.
    Cimino G, Anselmo AP, Cartoni C, et al. Secondary acute non lymphoid leukemia in patients treated for non Hodgkin’s lymphoma: no risk of therapy-related AML after PROVECIP schedule. Tumori. 1987;73:363.PubMedGoogle Scholar
  102. 102.
    Greene MH, Young RC, Merrill JM, DeVita VT. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin’s lymphoma. Cancer Res. 1983;43:1891.PubMedGoogle Scholar
  103. 103.
    Sacchi S, Marcheselli L, Bari A, et al. Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma: a 16-year follow-up study. Haematologica. 2008;93:398.PubMedGoogle Scholar
  104. 104.
    Rosner F, Grunwald HW. Simultaneous occurrence of multiple myeloma and acute myeloblastic leukemia: fact or myth? Am J Med. 1984;76:89.Google Scholar
  105. 105.
    Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council’s working party on leukaemia in adults. Br J Cancer. 1987;55:523.PubMedGoogle Scholar
  106. 106.
    Bergsagel DE, Bailey AJ, Langley GR, et al. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979;301:743.PubMedGoogle Scholar
  107. 107.
    Rund D, Krichevsky S, Bar-Cohen S, et al. Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia. 2005;19:1919.PubMedGoogle Scholar
  108. 108.
    Reimer RR, Hoover R, Fraumeni JF, Young RC. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med. 1977;297:177.PubMedGoogle Scholar
  109. 109.
    Pedersen-Bjergaard J, Nissen NI, Sorensen HM, et al. Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (dihydroxybusulfan). Cancer. 1980;45:19.PubMedGoogle Scholar
  110. 110.
    Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med. 1986;105:360.PubMedGoogle Scholar
  111. 111.
    Kaldor JM, Day NE, Pettersson F, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med. 1990;322:1.PubMedGoogle Scholar
  112. 112.
    Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999;340:351.PubMedGoogle Scholar
  113. 113.
    Pautier P, Joly F, Kerbrat P, et al. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol. 2010;116:157.PubMedGoogle Scholar
  114. 114.
    Gupta B, Sait SN, Block AW, et al. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) following treatment for ovarian cancer. J Clin Oncol. 2007;25:17506. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Google Scholar
  115. 115.
    du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320.PubMedGoogle Scholar
  116. 116.
    Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet. 1991;338:359.PubMedGoogle Scholar
  117. 117.
    Bajorin DF, Motzer RJ, Rodriguez E, et al. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst. 1993;85:60.PubMedGoogle Scholar
  118. 118.
    Bokemeyer C, Schmoll HJ. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol. 1993;11:1703.PubMedGoogle Scholar
  119. 119.
    Nichols CR, Breeden ES, Loehrer PJ, et al. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst. 1993;85:36.PubMedGoogle Scholar
  120. 120.
    van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk following testicular cancer: a follow-up study of 1909 patients. J Clin Oncol. 1993;11:415.PubMedGoogle Scholar
  121. 121.
    Redman JR, Vugrin D, Arlin ZA, et al. Leukemia following treatment of germ cell tumors in men. J Clin Oncol. 1984;2:1080.PubMedGoogle Scholar
  122. 122.
    Nichols CR, Hoffman R, Einhorn LH, et al. Hematologic malignancies associated with primary mediastinal germ-cell tumors. Ann Intern Med. 1985;102:603.PubMedGoogle Scholar
  123. 123.
    Roth BJ, Greist A, Kubilis PS, et al. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol. 1988;6:1239.PubMedGoogle Scholar
  124. 124.
    van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk following testicular cancer: a follow-up study of 1909 patients. J Clin Oncol. 1993;11:415.PubMedGoogle Scholar
  125. 125.
    Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316:1435.PubMedGoogle Scholar
  126. 126.
    Boshoff C, Begent RH, Oliver RT, et al. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol. 1995;6:35.PubMedGoogle Scholar
  127. 127.
    Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999;17:569.PubMedGoogle Scholar
  128. 128.
    Bokemeyer C, Schmoll HJ, Kuczyk MA, et al. Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst. 1995;87:58.PubMedGoogle Scholar
  129. 129.
    Kollmannsberger C, Beyer J, Droz JP, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol. 1998;16:3386.PubMedGoogle Scholar
  130. 130.
    Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer. 1999;83:860.PubMedGoogle Scholar
  131. 131.
    Hartmann JT, Nichols CR, Droz JP, et al. The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer. 2000;88:2629.PubMedGoogle Scholar
  132. 132.
    Hartmann JT, Nichols CR, Droz JP, et al. Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst. 2000;92:54.PubMedGoogle Scholar
  133. 133.
    Valagussa P, Tancini G, Bonadonna G. Second malignancies after CMF for resectable breast cancer. J Clin Oncol. 1987;5:1138.PubMedGoogle Scholar
  134. 134.
    Tallman MS, Gray R, Bennett JM, et al. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol. 1995;13:1557.PubMedGoogle Scholar
  135. 135.
    Diamandidou E, Buzdar AU, Smith TL, et al. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 1996;14:2722.PubMedGoogle Scholar
  136. 136.
    Campone M, Roche H, Kerbrat P. Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. Ann Oncol. 2005;16:1343.PubMedGoogle Scholar
  137. 137.
    Praga C, Bergh J, Bliss J. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005;23:4179.PubMedGoogle Scholar
  138. 138.
    Martin MG, Welch JS, Luo J, et al. Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat. 2009;118(3):593.PubMedGoogle Scholar
  139. 139.
    Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007;25:292.PubMedGoogle Scholar
  140. 140.
    Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicincyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 2003;21:1195.PubMedGoogle Scholar
  141. 141.
    Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99(3):196–205.PubMedGoogle Scholar
  142. 142.
    Kirova YM, Gambotti L, De Rycke Y, et al. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys. 2007;68:359.PubMedGoogle Scholar
  143. 143.
    Taylor PR, Jackson GH, Lennard AL, et al. Low incidence of myelodysplastic syndrome following transplantation using autologous non-cryopreserved bone marrow. Leukemia. 1997;11:1650.PubMedGoogle Scholar
  144. 144.
    Pedersen-Bjergaard J, Pedersen M, Myhre J, Geisler C. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia. 1997;11:1654.PubMedGoogle Scholar
  145. 145.
    Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87:3633.PubMedGoogle Scholar
  146. 146.
    André M, Henry-Amar M, Blaise D, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin’s disease. Blood. 1998;92:1933.PubMedGoogle Scholar
  147. 147.
    Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95:1588.PubMedGoogle Scholar
  148. 148.
    Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12:2527.PubMedGoogle Scholar
  149. 149.
    Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3128.PubMedGoogle Scholar
  150. 150.
    Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:2208.PubMedGoogle Scholar
  151. 151.
    Sobecks RM, Le Beau MM, Anastasi J, Williams SF. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;23:1161.PubMedGoogle Scholar
  152. 152.
    Milligan DW, Ruiz DEM, Kolb HJ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT lymphoma and late effects working parties. European group for blood and marrow transplantation. Br J Haematol. 1999;106:1020.PubMedGoogle Scholar
  153. 153.
    Harrison CN, Gregory W, Hudson GV, et al. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin’s disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer. 1999;81:476.PubMedGoogle Scholar
  154. 154.
    Micallef IN, Lillington DM, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000;18:947.PubMedGoogle Scholar
  155. 155.
    Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;101:2015.PubMedGoogle Scholar
  156. 156.
    Lenz G, Dreyling M, Schiegnitz E, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol. 2004;22:4926.PubMedGoogle Scholar
  157. 157.
    Laughlin MJ, McGaughey DS, Crews JR, et al. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol. 1998;16:1008.PubMedGoogle Scholar
  158. 158.
    Martinez-Climent JA, Comes AM, Vizcarra E, et al. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome. Bone Marrow Transplant. 2000;25:1203.PubMedGoogle Scholar
  159. 159.
    Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol. 1996;95:349.PubMedGoogle Scholar
  160. 160.
    Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95:1588.PubMedGoogle Scholar
  161. 161.
    Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;101:2015.PubMedGoogle Scholar
  162. 162.
    Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 1994;12:2535.PubMedGoogle Scholar
  163. 163.
    Mach-Pascual S, Legare RD, Lu D, et al. Predictive value of clonality assays in patients with non-Hodgkin’s lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood. 1998;91:4496.PubMedGoogle Scholar
  164. 164.
    Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997;34:17.PubMedGoogle Scholar
  165. 165.
    Tatarsky I, Sharon R. Management of polycythemia vera with hydroxyurea. Semin Hematol. 1997;34:24.PubMedGoogle Scholar
  166. 166.
    Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol. 1994;52:134.PubMedGoogle Scholar
  167. 167.
    Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370.PubMedGoogle Scholar
  168. 168.
    Thoennissen NH, Krug UO, Lee DH. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010;115:2882.PubMedGoogle Scholar
  169. 169.
    Casciato DA, Scott JL. Acute leukemia following prolonged cytotoxic agent therapy. Medicine. 1979;58:32.PubMedGoogle Scholar
  170. 170.
    O’Gara RW, Adamson RH, Kelly MG, Dalgard DW. Neoplasms of the hematopoietic system in nonhuman primates: report of one spontaneous tumor and two leukemias induced by procarbazine. J Natl Cancer Inst. 1971;46:1121.PubMedGoogle Scholar
  171. 171.
    Vismans JJ, Briet E, Meijer K, den Ottolander GJ. Azathioprine and subacute myelomonocytic leukemia. Acta Med Scand. 1980;207:315.PubMedGoogle Scholar
  172. 172.
    Carver JH, Hatch FT, Branscomb EW. Estimating maximum limits to mutagenic potency from cytotoxic potency. Nature. 1979;279:154.PubMedGoogle Scholar
  173. 173.
    Valagussa P, Santoro A, Kenda R, et al. Second malignancies in Hodgkin’s disease: a complication of certain forms of treatment. BMJ. 1980;280:216.PubMedGoogle Scholar
  174. 174.
    Offman J, Opelz G, Doehler B, et al. Defective DNAmismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood. 2004;104:822.PubMedGoogle Scholar
  175. 175.
    Xue Y, Lu D, Guo Y, Lin B. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leuk Res. 1992;16:1113.PubMedGoogle Scholar
  176. 176.
    Rinsky RA, Young RJ, Smith AB. Leukemia in benzene workers. Am J Ind Med. 1981;2:217.PubMedGoogle Scholar
  177. 177.
    Ginevan ME. Nonlymphatic leukemias and adult exposure to diagnostic X-rays: the evidence reconsidered. Health Phys. 1980;38:129.PubMedGoogle Scholar
  178. 178.
    Land CE. Estimating cancer risks from low doses of ionizing radiation. Science. 1980;209:1197.PubMedGoogle Scholar
  179. 179.
    Major IR, Mole RH. Myeloid leukaemia in x-ray irradiated CBA mice. Nature. 1978;272:455.PubMedGoogle Scholar
  180. 180.
    Seed TM, Tolle DV, Fritz TE, et al. Irradiation-induced erythroleukemia and myelogenous leukemia in the beagle dog: hematology and ultrastructure. Blood. 1977;50:1061.PubMedGoogle Scholar
  181. 181.
    Elias L, Hoffman R, Boswell S, et al. A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes: I. Clinical results. Leukemia. 1987;1:105.PubMedGoogle Scholar
  182. 182.
    Coleman CN, Williams CJ, Flint A, et al. Hematologic neoplasia in patients treated for Hodgkin’s disease. N Engl J Med. 1977;297:1249.PubMedGoogle Scholar
  183. 183.
    De Braekeleer M. Cytogenetic studies in secondary leukemia: statistical analysis. Oncology. 1986;43:358.PubMedGoogle Scholar
  184. 184.
    Wright JD, St Clair CM, Deutsch I, et al. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer. 2010;116:2486.PubMedGoogle Scholar
  185. 185.
    Josting A, Wiedenmann S, Franklin J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2003;21:3440.PubMedGoogle Scholar
  186. 186.
    Galvani DW, Nethersell AB, Cawley JC. Alpha-interferon in myelodysplasia; clinical observations and effects on NK cells. Leuk Res. 1988;12:257.PubMedGoogle Scholar
  187. 187.
    Cheson BD. The myelodysplastic syndromes: current approaches to therapy. Ann Intern Med. 1990;112:932.PubMedGoogle Scholar
  188. 188.
    Koeffler HP, Hirji K, Itri L. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep. 1985;69:1399.PubMedGoogle Scholar
  189. 189.
    Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567.PubMedGoogle Scholar
  190. 190.
    Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324:1385.PubMedGoogle Scholar
  191. 191.
    Koeffler HP, Heitjan D, Mertelsmann R, et al. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. Blood. 1988;71:703.PubMedGoogle Scholar
  192. 192.
    Clark RE, Ismail SA, Jacobs A, et al. A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome. Br J Haematol. 1987;66:77.PubMedGoogle Scholar
  193. 193.
    Kurzrock R, Estey E, Talpaz M. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol. 1993;11:1489.PubMedGoogle Scholar
  194. 194.
    Schlenk RF, Fröhling S, Hartmann F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia. 2004;18:1798.PubMedGoogle Scholar
  195. 195.
    Estrov Z, Kurzrock R, Talpaz M, et al. Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. Ann Hematol. 1991;63:297.PubMedGoogle Scholar
  196. 196.
    Willemze R, van der Lely N, Zwierzina H, et al. A randomized phase-I/II multicenter study of recombinant human granulocyte- macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. Ann Hematol. 1992;64:173.PubMedGoogle Scholar
  197. 197.
    Ganser A, Seipelt G, Lindemann A, et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood. 1990;76:455.PubMedGoogle Scholar
  198. 198.
    Ganser A, Volkers B, Greher J, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes—a phase I/II trial. Blood. 1989;73:31.PubMedGoogle Scholar
  199. 199.
    Negrin RS, Haeuber DH, Nagler A, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony stimulating factor. A phase I–II trial. Ann Intern Med. 1989;110:976.PubMedGoogle Scholar
  200. 200.
    Vadhan-Raj S, Keating M, LeMaistre A, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987;317:1545.PubMedGoogle Scholar
  201. 201.
    Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92:68.PubMedGoogle Scholar
  202. 202.
    Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol. 1986;4:1857.PubMedGoogle Scholar
  203. 203.
    Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7 Suppl 1:21.PubMedGoogle Scholar
  204. 204.
    Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107:7473.PubMedGoogle Scholar
  205. 205.
    Preisler HD, Early AP, Raza A, et al. Therapy of secondary acute non-lymphocytic leukemia with cytarabine. N Engl J Med. 1983;308:21.PubMedGoogle Scholar
  206. 206.
    Kantarjian H, Beran M, Cortes J, O’Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006;106:1099.PubMedGoogle Scholar
  207. 207.
    Takeyama K, Seto M, Uike N, et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol. 2000;71:144.PubMedGoogle Scholar
  208. 208.
    Estey E, Thall P, Beran M, et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997;90:2969.PubMedGoogle Scholar
  209. 209.
    Fenaux P, Lucidarme D, Lai JL, Bauters F. Favorable cytogenetic abnormalities in secondary leukemia. Cancer. 1989;63:2505.PubMedGoogle Scholar
  210. 210.
    Lee EJ, George SL, Caligiuri M, et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or with- out the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420. J Clin Oncol. 1999;17:2831.PubMedGoogle Scholar
  211. 211.
    Ballen KK, Gilliland DG, Guinan EC, et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant. 1997;20:737.PubMedGoogle Scholar
  212. 212.
    Anderson JE. Bone marrow transplantation for myelodysplasia. Blood Rev. 2000;14:63.PubMedGoogle Scholar
  213. 213.
    Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood. 1997;89:2578.PubMedGoogle Scholar
  214. 214.
    Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients—report of the French society of bone marrow transplantation. J Clin Oncol. 2000;18:963.PubMedGoogle Scholar
  215. 215.
    Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia. 1998;12 Suppl 1:S25.PubMedGoogle Scholar
  216. 216.
    Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood. 2000;95:1188.PubMedGoogle Scholar
  217. 217.
    Berg JW. The incidence of multiple primary cancers. I. Development of further cancers in patients with lymphomas, leukemias, and myeloma. J Natl Cancer Inst. 1967;38:741.PubMedGoogle Scholar
  218. 218.
    Mathe G, Tubiana M, Calman F, et al. Acute leukemia syndromes (ALS) appearing during the evolution of hematosarcomas and chronic leukemias (clinical analysis). Nouv Rev Fr Hematol. 1967;7:543.PubMedGoogle Scholar
  219. 219.
    Newell GR, Krementz ET, Roberts JD, Kinnear BK. Multiple primary neoplasms in blacks compared to whites. I. Further cancers in patients with Hodgkin’s disease, leukemia, and myeloma. J Natl Cancer Inst. 1974;52:635.PubMedGoogle Scholar
  220. 220.
    Newman DR, Maldonado JE, Harrison EG, et al. Myelomonocytic leukemia in Hodgkin’s disease. Cancer. 1970;25:128.PubMedGoogle Scholar
  221. 221.
    Kjeldsberg CR, Nathwani BN, Rappaport H. Acute myeloblastic leukemia developing in patients with mediastinal lymphoblastic lymphoma. Cancer. 1979;44:2316.PubMedGoogle Scholar
  222. 222.
    Rosner F, Grunwald HW. Multiple myeloma and Waldenstrom’s macroglobulinemia terminating in acute leukemia. Review with emphasis on karyotypic and ultrastructural abnormalities. N Y State J Med. 1980;80:558.PubMedGoogle Scholar
  223. 223.
    Zech L, Haglund U, Nilsson K, Klein G. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer. 1976;17:47.PubMedGoogle Scholar
  224. 224.
    Lundberg WB, Farber LR, Cadman EC, Skeel RT. Spontaneous acute leukemia in polycythemia vera. Ann Intern Med. 1976;84:294.PubMedGoogle Scholar
  225. 225.
    Miller JA. Carcinogenesis by chemicals: an overview—G. H. A. Clowes Memorial Lecture. Cancer Res. 1970;30:559.PubMedGoogle Scholar
  226. 226.
    Carey RW, Holland JF, Sheehe PR, Graham S. Association of cancer of the breast and acute myelocytic leukemia. Cancer. 1967;20:1080.PubMedGoogle Scholar
  227. 227.
    Whang-Peng J, Lee EC, Minna JD, et al. Deletion of 3(p14; p23) in secondary erythroleukemia arising in long-term survivors of small cell lung cancer. J Natl Cancer Inst. 1988;80:1253.PubMedGoogle Scholar
  228. 228.
    Ladanyi M, Samaniego F, Reuter VE, et al. Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors. J Natl Cancer Inst. 1990;82:221.PubMedGoogle Scholar
  229. 229.
    Chaganti RS, Ladanyi M, Samaniego F, et al. Leukemic differentiation of a mediastinal germ cell tumor. Genes Chromosomes Cancer. 1989;1:83.PubMedGoogle Scholar
  230. 230.
    Nichols CR, Roth BJ, Heerema N, et al. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med. 1990;322:1425.PubMedGoogle Scholar
  231. 231.
    Gatti RA, Good RA. Occurrence of malignancy in immuno­deficiency diseases. A literature review. Cancer. 1971;28:89.PubMedGoogle Scholar
  232. 232.
    Keast D. Immunosurveillance and cancer. Lancet. 1970;2:710.PubMedGoogle Scholar
  233. 233.
    Lacher MJ. Long survival in Hodgkin’s disease. Ann Intern Med. 1969;70:7.PubMedGoogle Scholar
  234. 234.
    Smetana HF. Hodgkin’s disease: a follow-up study of patients surviving more than twenty years after the original diagnosis. J Pathol. 1969;98:231.PubMedGoogle Scholar
  235. 235.
    Miller EC. Some current perspectives on chemical carcinogenesis in humans and experimental animals: Presidential Address. Cancer Res. 1978;38:1479.PubMedGoogle Scholar
  236. 236.
    Singer B. N-nitroso alkylating agents: formation and persistence of alkyl derivatives in mammalian nucleic acids as contributing factors in carcinogenesis. J Natl Cancer Inst. 1979;62:1329.PubMedGoogle Scholar
  237. 237.
    Schmid E, Bauchinger M. Comparison of the chromosome damage induced by radiation and cytoxan therapy in lymphocytes of patients with gynaecological tumours. Mutat Res. 1973;21:271.PubMedGoogle Scholar
  238. 238.
    Genuardi M, Zollino M, Serra A, et al. Long-term cytogenetic effects of antineoplastic treatment in relation to secondary leukemia. Cancer Genet Cytogenet. 1988;33:201.PubMedGoogle Scholar
  239. 239.
    Thirman MJ, Gill HJ, Burnett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med. 1993;329:909.PubMedGoogle Scholar
  240. 240.
    Yunis JJ. The chromosomal basis of human neoplasia. Science. 1983;221:227.PubMedGoogle Scholar
  241. 241.
    Pelicci PG, Lanfrancone L, Brathwaite MD, et al. Amplification of the c-myb oncogene in a case of human acute myelogenous leukemia. Science. 1984;224:1117.PubMedGoogle Scholar
  242. 242.
    Blick M, Westin E, Gutterman J, et al. Oncogene expression in human leukemia. Blood. 1984;64:1234.PubMedGoogle Scholar
  243. 243.
    Horiike S, Yokota S, Nakao M, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia. 1997;11:1442.PubMedGoogle Scholar
  244. 244.
    LeBeau MM, Rowley JD. Heritable fragile sites in cancer. Nature. 1984;308:607.PubMedGoogle Scholar
  245. 245.
    Pedersen-Bjergaard J, Andersen MK, Andersen MT. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008;22:240.PubMedGoogle Scholar
  246. 246.
    Andersen MT, Andersen MK, Christiansen DH, et al. NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features. Leukemia. 2008;22:951.PubMedGoogle Scholar
  247. 247.
    Nakagawa T, Saitoh S, Imoto S, et al. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology. 1992;49:114.PubMedGoogle Scholar
  248. 248.
    Paquette RL, Landaw EM, Pierre RV, et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood. 1993;82:590.PubMedGoogle Scholar
  249. 249.
    Sherr CJ, Rettenmier CW. The fms gene and the CSF-1 receptor. Cancer Surv. 1986;5:221.PubMedGoogle Scholar
  250. 250.
    Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem. 1988;57:443.PubMedGoogle Scholar
  251. 251.
    Roussel MF, Downing JR, Rettenmier CW, Sherr CJ. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential. Cell. 1988;55:979.PubMedGoogle Scholar
  252. 252.
    Woolford J, McAuliffe A, Rohrschneider LR. Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype. Cell. 1988;55:965.PubMedGoogle Scholar
  253. 253.
    Taylor C, McGlynn H, Carter G, et al. RAS and FMS mutations following cytotoxic therapy for childhood acute lymphoblastic leukaemia. Leukemia. 1995;9:466.PubMedGoogle Scholar
  254. 254.
    Carter G, Ridge S, Padua RA. Genetic lesions in preleukemia. Crit Rev Oncog. 1992;3:339.PubMedGoogle Scholar
  255. 255.
    Ridge SA, Worwood M, Oscier D, et al. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci USA. 1990;87:1377.PubMedGoogle Scholar
  256. 256.
    Tobal K, Pagliuca A, Bhatt B, et al. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia. 1990;4:486.PubMedGoogle Scholar
  257. 257.
    Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453.PubMedGoogle Scholar
  258. 258.
    Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49.PubMedGoogle Scholar
  259. 259.
    Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood. 1994;84:2391.PubMedGoogle Scholar
  260. 260.
    Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood. 1994;84:2412.PubMedGoogle Scholar
  261. 261.
    Sugimoto K, Hirano N, Toyoshima H, et al. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood. 1993;81:3022.PubMedGoogle Scholar
  262. 262.
    Jonveaux P, Fenaux P, Quiquandon I, et al. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene. 1991;6:2243.PubMedGoogle Scholar
  263. 263.
    Slingerland JM, Minden MD, Benchimol S. Mutation of the p53 gene in human acute myelogenous leukemia. Blood. 1991;77:1500.PubMedGoogle Scholar
  264. 264.
    Fenaux P, Jonveaux P, Quiquandon I, et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood. 1991;78:1652.PubMedGoogle Scholar
  265. 265.
    Fenaux P, Preudhomme C, Quiquandon I, et al. Mutations of the P53 gene in acute myeloid leukaemia. Br J Haematol. 1992;80:178.PubMedGoogle Scholar
  266. 266.
    Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994;84:3148.PubMedGoogle Scholar
  267. 267.
    Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol. 2001;19:1405.PubMedGoogle Scholar
  268. 268.
    Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986;323:643.PubMedGoogle Scholar
  269. 269.
    Weinberg RA. The Rb gene and the negative regulation of cell growth. Blood. 1989;74:529.PubMedGoogle Scholar
  270. 270.
    Kornblau SM, Xu HJ, Zhang W, et al. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood. 1994;84:256.PubMedGoogle Scholar
  271. 271.
    Ahuja HG, Jat PS, Foti A, et al. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood. 1991;78:3259.PubMedGoogle Scholar
  272. 272.
    Kornblau SM, Xu HJ, del Giglio A, et al. Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Res. 1992;52:4587.PubMedGoogle Scholar
  273. 273.
    Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood. 1994;84:4038.PubMedGoogle Scholar
  274. 274.
    Ogawa S, Hirano N, Sato N, et al. Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood. 1994;84:2431.PubMedGoogle Scholar
  275. 275.
    Cayuela JM, Hebert J, Sigaux F. Homozygous MTS1 (p16INK4A) deletion in primary tumor cells of 163 leukemic patients. Blood. 1995;85:854.PubMedGoogle Scholar
  276. 276.
    Quesnel B, Fenaux P. P15INK4b gene methylation and myelodysplastic syndromes. Leuk Lymphoma. 1999;35:437.PubMedGoogle Scholar
  277. 277.
    Tien HF, Tang JL, Tsay W, et al. Methylation of the p15INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol. 2001;112:148.PubMedGoogle Scholar
  278. 278.
    Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2003;17:1813.PubMedGoogle Scholar
  279. 279.
    Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood. 2004;104:1474.PubMedGoogle Scholar
  280. 280.
    Tasaka T, Lee S, Spira S, et al. Microsatellite instability during the progression of acute myelocytic leukaemia. Br J Haematol. 1997;98:219.PubMedGoogle Scholar
  281. 281.
    Rimsza LM, Kopecky KJ, Ruschulte J, et al. Microsatellite instability is not a defining genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature. Leukemia. 2000;14:1044.PubMedGoogle Scholar
  282. 282.
    Ben-Yehuda D, Krichevsky S, Caspi O, et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood. 1996;88:4296.PubMedGoogle Scholar
  283. 283.
    Worrillow LJ, Travis LB, Smith AG, et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res. 2003;9:3012.PubMedGoogle Scholar
  284. 284.
    Zhu YM, Das-Gupta EP, Russell NH. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood. 1999;94:733.PubMedGoogle Scholar
  285. 285.
    Nisse C, Lorthois C, Dorp V, et al. Exposure to occupational and environmental factors in myelodysplastic syndromes. Preliminary results of a case-control study. Leukemia. 1995;9:693.PubMedGoogle Scholar
  286. 286.
    West RR, Stafford DA, White AD, et al. Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. Blood. 2000;95:2093.PubMedGoogle Scholar
  287. 287.
    Seedhouse C, Russell N. Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br J Haematol. 2007;137(6):513–29.PubMedGoogle Scholar
  288. 288.
    Rothman N, Smith MT, Hayes RB, et al. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609 C–>T mutation and rapid fractional excretion of chlorzoxa- zone. Cancer Res. 1997;57:2839.PubMedGoogle Scholar
  289. 289.
    Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609 C–>T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy- related myeloid leukemia. Blood. 1999;94:803.PubMedGoogle Scholar
  290. 290.
    Fern L, Pallis M, Ian Carter G, et al. Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol. 2004;126:63.PubMedGoogle Scholar
  291. 291.
    Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30:445.PubMedGoogle Scholar
  292. 292.
    Chen H, Sandler DP, Taylor JA, et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet. 1996;347:295.PubMedGoogle Scholar
  293. 293.
    Preudhomme C, Nisse C, Hebbar M, et al. Glutathione S transferase theta 1 gene defects in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens. Leukemia. 1997;11:1580.PubMedGoogle Scholar
  294. 294.
    Atoyebi W, Kusec R, Fidler C, et al. Glutathione S-transferase gene deletions in myelodysplasia. Lancet. 1997;349:1450.PubMedGoogle Scholar
  295. 295.
    Sasai Y, Horiike S, Misawa S, et al. Genotype of glutathione S- transferase and other genetic configurations in myelodysplasia. Leuk Res. 1999;23:975.PubMedGoogle Scholar
  296. 296.
    Alexandrie AK, Sundberg MI, Seidegard J, et al. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: A study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis. 1994;15:1785.PubMedGoogle Scholar
  297. 297.
    Kawajiri K, Nakachi K, Imai K, et al. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol. 1993;14:77.PubMedGoogle Scholar
  298. 298.
    Miller EC, Miller JA. Mechanisms of chemical carcinogenesis. Cancer. 1981;47:1055.PubMedGoogle Scholar
  299. 299.
    Fialkow PJ, Singer JW, Adamson JW, et al. Acute nonlymphocytic leukemia: expression in cells restricted to granulocytic and monocytic differentiation. N Engl J Med. 1979;301:1.PubMedGoogle Scholar
  300. 300.
    Fialkow PJ, Singer JW, Adamson JW, et al. Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood. 1981;57:1068.PubMedGoogle Scholar
  301. 301.
    Wiggans RG, Jacobson RJ, Fialkow PJ, et al. Probable clonal origin of acute myeloblastic leukemia following radiation and chemotherapy of colon cancer. Blood. 1978;52:659.PubMedGoogle Scholar
  302. 302.
    Busque L, Gilliland DG, Prchal JT, et al. Clonality in juvenile chronic myelogenous leukemia. Blood. 1995;85:21.PubMedGoogle Scholar
  303. 303.
    Lyon MF. The William Allan memorial award address: X-chromosome inactivation and the location and expression of X-linked genes. Am J Hum Genet. 1988;42:8.PubMedGoogle Scholar
  304. 304.
    Beutler E, Collins Z, Irwin LE. Value of genetic variants of glucose-6-phosphate dehydrogenase in tracing the origin of malignant tumors. N Engl J Med. 1967;276:389.PubMedGoogle Scholar
  305. 305.
    Vogelstein B, Fearon ER, Hamilton SR, Feinberg AP. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science. 1985;227:642.PubMedGoogle Scholar
  306. 306.
    Vogelstein B, Fearon ER, Hamilton SR, et al. Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res. 1987;47:4806.PubMedGoogle Scholar
  307. 307.
    Allen RC, Zoghbi HY, Moseley AB, et al. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51:1229.PubMedGoogle Scholar
  308. 308.
    Boyd Y, Fraser NJ. Methylation patterns at the hypervariable X- chromosome locus DXS255 (M27 beta): Correlation with X-inactivation status. Genomics. 1990;7:182.PubMedGoogle Scholar
  309. 309.
    Busque L, Gilliland DG. Clonal evolution in acute myeloid leukemia. Blood. 1993;82:337.PubMedGoogle Scholar
  310. 310.
    Fey MF, Liechti-Gallati S, von Rohr A, et al. Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probe. Blood. 1994;83:931.PubMedGoogle Scholar
  311. 311.
    Busque L, Zhu J, DeHart D, et al. An expression based clonality assay at the human androgen receptor locus (HUMARA) on chromosome X. Nucleic Acids Res. 1994;22:697.PubMedGoogle Scholar
  312. 312.
    Willman CL, Busque L, Griffith BB, et al. Langerhans’-cell histiocytosis (histiocytosis X)—a clonal proliferative disease. N Engl J Med. 1994;331:154.PubMedGoogle Scholar
  313. 313.
    Prchal JT, Guan YL, Prchal JF, Barany F. Transcriptional analysis of the active X-chromosome in normal and clonal hematopoiesis. Blood. 1993;81:269.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Gabriela Bernadeta Iwanski
    • 1
  • Nils Heinrich Thoennissen
    • 1
  • Dorothy J. Park
    • 2
  • H. Phillip Koeffler
    • 3
  1. 1.Division of Hematology/OncologyUniversity Hospital of MuensterMuensterGermany
  2. 2.Division of Hematology/OncologyTower Hematology Oncology Medical Group, Cedars-Sinai Medical Center, UCLA School of MedicineBeverly HillsUSA
  3. 3.Department of Medicine/Hematology-OncologyUCLA/Cedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations